Keywords:
Molecular imaging, Nuclear medicine, Oncology, PET, PET-CT, Diagnostic procedure, Staging, Cancer
Authors:
A. Gaber, R. Núñez, E. Delpassand; HOUSTON, TX/US
DOI:
10.26044/ecr2021/C-10556
Purpose
Prostate cancer is considered the most common type of malignancy in men worldwide. At least 2 million men in the United States develop or have prostate cancer with 200,000 new cases diagnosed annually, leading to approximately 30,000 deaths per year. Imaging plays an important role in many aspects of the management of this disease. Since prostate-specific membrane antigen is well known to be overexpressed in most prostate cancers, efforts have been made to develop ligands for this target, either for PET/CT imaging or radioligand Therapy. Whole-body 68Ga-PSMA-11 PET/CT scan is a novel and promising radioligand having high sensitivity in detecting prostate cancer lesions with a high tumor to background contrast, even at low serum prostate-specific antigen levels.